{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-029992","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.318874+00:00","generated_at":"2026-05-15T09:55:23.075210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dogwood Therapeutics Q4 loss $3.8M; Halneuron Phase 2b >50% enrolled, top-line Q3 2026","bullets":["Net loss Q4 2025 $3.8M ($0.26/share) vs $8.2M ($6.29) in Q4 2024; full year loss $35.5M ($7.13).","Cash $6.5M at Dec 31, 2025; Jan 2026 financing raised $11.4M net to fund through Phase 2b readout.","Halneuron CINP Phase 2b >50% enrolled; interim analysis showed separation from placebo; top-line expected Q3 2026.","R&D expenses FY 2025 $21.8M (up from $3.5M) due to $12.0M SP16 license fee and clinical trial costs.","G&A expenses fell to $6.1M from $8.7M due to lower nonrecurring transaction costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-029992","json":"https://secwatch.observer/filing/0001104659-26-029992.json","markdown":"https://secwatch.observer/filing/0001104659-26-029992.md","text":"https://secwatch.observer/filing/0001104659-26-029992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/0001104659-26-029992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/dwtx-20260318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:55:23.075210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}